🇺🇸 FDA
Patent

US 10973879

Use of a VEGF antagonist to treat angiogenic eye disorders

granted A61KA61K38/179A61K47/65

Quick answer

US patent 10973879 (Use of a VEGF antagonist to treat angiogenic eye disorders) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/179, A61K47/65, A61K9/0019, A61P